Here are five key notes:
1. The company reported revenue great 6.5 percent over the same period last year to hit $20.9 million. The company generated around $245,000 of original equipment manufacturer sales from a large orthopedic device manufacturer.
2. The company’s revenue from service lines include:
• Biologics: 15.5 percent growth to $9.7 million
• Fixation (excluding OEM): 12.3 percent growth to $10.3 million
• OEM: 6.1 percent decline to $745,000.
3. The company reported gross profit at around $13.7 million, which was 65.5 percent of revenue compared to $13.2 million or 67.3 percent of revenue for the same period last year.
4. The net loss for the third quarter was $5.4 million for the third quarter and $16.1 million for the nine months end. The third quarter 2015 EBITDA loss was around $915,000.
5. The company expects 2015 revenue to reach $43 million to $46 million for the second half of the year.
More articles on orthopedic devices:
18 spine devices receive FDA 510(k) clearance in October
AxiaLIF could save $3.5k per spine surgery: 5 key notes
Europe spine surgery devices market to grow at a CAGR of 6% to 2020: 3 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
